Suranganie Dharmawardhane
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| rac GTP-Binding Proteins | 8 | 2022 | 22 | 3.870 |
Why?
|
| cdc42 GTP-Binding Protein | 6 | 2021 | 23 | 3.000 |
Why?
|
| Breast Neoplasms | 17 | 2021 | 1502 | 2.720 |
Why?
|
| rac1 GTP-Binding Protein | 5 | 2021 | 46 | 2.100 |
Why?
|
| Stilbenes | 8 | 2016 | 44 | 2.040 |
Why?
|
| Carbazoles | 7 | 2021 | 42 | 1.950 |
Why?
|
| Antineoplastic Agents | 9 | 2019 | 803 | 1.940 |
Why?
|
| Pyrimidines | 7 | 2021 | 118 | 1.790 |
Why?
|
| Vitis | 4 | 2016 | 31 | 1.280 |
Why?
|
| Cell Line, Tumor | 20 | 2021 | 2231 | 1.140 |
Why?
|
| Isoflavones | 5 | 2021 | 129 | 1.100 |
Why?
|
| Neoplasm Metastasis | 7 | 2017 | 219 | 1.040 |
Why?
|
| Eukaryotic Initiation Factor-4G | 3 | 2015 | 11 | 1.030 |
Why?
|
| Catechin | 3 | 2016 | 31 | 0.980 |
Why?
|
| Quercetin | 3 | 2016 | 45 | 0.960 |
Why?
|
| Genistein | 3 | 2016 | 42 | 0.910 |
Why?
|
| Gene Expression Regulation, Neoplastic | 5 | 2021 | 807 | 0.880 |
Why?
|
| GTP-Binding Proteins | 1 | 2022 | 60 | 0.850 |
Why?
|
| Protein Kinase Inhibitors | 1 | 2021 | 122 | 0.740 |
Why?
|
| Enzyme Inhibitors | 2 | 2013 | 433 | 0.740 |
Why?
|
| Cell Proliferation | 12 | 2021 | 1198 | 0.720 |
Why?
|
| Cell Movement | 7 | 2022 | 571 | 0.710 |
Why?
|
| Proto-Oncogene Proteins c-myc | 3 | 2015 | 54 | 0.700 |
Why?
|
| Mice | 15 | 2022 | 5913 | 0.690 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 1 | 2021 | 182 | 0.690 |
Why?
|
| Drug Resistance, Neoplasm | 1 | 2021 | 222 | 0.680 |
Why?
|
| Saccharomycetales | 1 | 2018 | 7 | 0.650 |
Why?
|
| Cell Polarity | 1 | 2018 | 54 | 0.630 |
Why?
|
| Mice, Nude | 7 | 2016 | 337 | 0.610 |
Why?
|
| Proto-Oncogene Proteins c-akt | 5 | 2016 | 269 | 0.600 |
Why?
|
| Mammary Neoplasms, Experimental | 2 | 2009 | 70 | 0.600 |
Why?
|
| Female | 24 | 2021 | 20969 | 0.570 |
Why?
|
| Cell Survival | 8 | 2017 | 864 | 0.560 |
Why?
|
| Tandem Mass Spectrometry | 2 | 2015 | 182 | 0.560 |
Why?
|
| Antineoplastic Agents, Phytogenic | 2 | 2016 | 110 | 0.550 |
Why?
|
| Neovascularization, Pathologic | 1 | 2017 | 127 | 0.550 |
Why?
|
| Chromatography, High Pressure Liquid | 2 | 2015 | 421 | 0.540 |
Why?
|
| Receptors, Estrogen | 3 | 2015 | 156 | 0.530 |
Why?
|
| Animals | 19 | 2022 | 15081 | 0.530 |
Why?
|
| Protein Biosynthesis | 2 | 2015 | 133 | 0.530 |
Why?
|
| Actins | 2 | 2007 | 148 | 0.520 |
Why?
|
| Signal Transduction | 4 | 2018 | 1908 | 0.510 |
Why?
|
| Drug Design | 2 | 2013 | 162 | 0.510 |
Why?
|
| Breast | 1 | 2016 | 135 | 0.510 |
Why?
|
| Mice, SCID | 4 | 2021 | 150 | 0.500 |
Why?
|
| Estradiol | 3 | 2007 | 262 | 0.480 |
Why?
|
| Humans | 30 | 2021 | 37093 | 0.450 |
Why?
|
| Phytoestrogens | 2 | 2012 | 38 | 0.440 |
Why?
|
| Immunologic Deficiency Syndromes | 1 | 2013 | 64 | 0.410 |
Why?
|
| Quinazolines | 1 | 2012 | 33 | 0.400 |
Why?
|
| Reishi | 1 | 2011 | 6 | 0.400 |
Why?
|
| Up-Regulation | 3 | 2021 | 513 | 0.380 |
Why?
|
| MicroRNAs | 1 | 2016 | 426 | 0.360 |
Why?
|
| Plant Extracts | 1 | 2013 | 286 | 0.350 |
Why?
|
| Neoplasms | 2 | 2018 | 1103 | 0.350 |
Why?
|
| Cytoskeleton | 2 | 2007 | 110 | 0.340 |
Why?
|
| p21-Activated Kinases | 3 | 2013 | 16 | 0.340 |
Why?
|
| Liver Neoplasms, Experimental | 1 | 2009 | 23 | 0.340 |
Why?
|
| Bone Neoplasms | 1 | 2009 | 45 | 0.330 |
Why?
|
| Fluorescent Dyes | 2 | 2006 | 181 | 0.320 |
Why?
|
| Aminoquinolines | 3 | 2013 | 14 | 0.320 |
Why?
|
| Neoplasms, Hormone-Dependent | 1 | 2007 | 16 | 0.290 |
Why?
|
| Luminescent Agents | 1 | 2006 | 3 | 0.290 |
Why?
|
| Luminescent Proteins | 1 | 2006 | 77 | 0.280 |
Why?
|
| Apoptosis | 4 | 2021 | 1398 | 0.280 |
Why?
|
| Spectrometry, Fluorescence | 1 | 2006 | 208 | 0.270 |
Why?
|
| Estrogens | 1 | 2007 | 202 | 0.260 |
Why?
|
| Cell Division | 2 | 2022 | 307 | 0.260 |
Why?
|
| Focal Adhesions | 1 | 2005 | 15 | 0.250 |
Why?
|
| Adenocarcinoma | 1 | 2007 | 251 | 0.250 |
Why?
|
| Down-Regulation | 2 | 2016 | 435 | 0.220 |
Why?
|
| Molecular Structure | 4 | 2019 | 492 | 0.220 |
Why?
|
| Dose-Response Relationship, Drug | 3 | 2019 | 1039 | 0.220 |
Why?
|
| Neoplasm Invasiveness | 3 | 2011 | 251 | 0.220 |
Why?
|
| Guanine Nucleotide Exchange Factors | 1 | 2022 | 29 | 0.220 |
Why?
|
| Drug Screening Assays, Antitumor | 2 | 2021 | 113 | 0.210 |
Why?
|
| Neoplasm Transplantation | 2 | 2012 | 122 | 0.200 |
Why?
|
| Cell Cycle | 2 | 2016 | 326 | 0.200 |
Why?
|
| Spheroids, Cellular | 1 | 2021 | 28 | 0.200 |
Why?
|
| Disease Models, Animal | 3 | 2021 | 1371 | 0.200 |
Why?
|
| Fatty Acids, Omega-3 | 2 | 2019 | 36 | 0.190 |
Why?
|
| Point Mutation | 1 | 2021 | 93 | 0.190 |
Why?
|
| Blotting, Western | 3 | 2014 | 859 | 0.190 |
Why?
|
| Estrogen Receptor beta | 3 | 2013 | 40 | 0.180 |
Why?
|
| Tumor Cells, Cultured | 5 | 2014 | 502 | 0.180 |
Why?
|
| Receptor, erbB-2 | 1 | 2021 | 133 | 0.180 |
Why?
|
| Eicosapentaenoic Acid | 1 | 2019 | 14 | 0.180 |
Why?
|
| Estrogen Receptor alpha | 3 | 2013 | 111 | 0.180 |
Why?
|
| MAP Kinase Signaling System | 1 | 2021 | 169 | 0.170 |
Why?
|
| Disease Progression | 3 | 2019 | 601 | 0.170 |
Why?
|
| Adipocytes | 1 | 2019 | 58 | 0.170 |
Why?
|
| Cell Communication | 1 | 2019 | 97 | 0.160 |
Why?
|
| Recombinant Fusion Proteins | 2 | 2012 | 295 | 0.160 |
Why?
|
| Indoles | 1 | 2019 | 158 | 0.160 |
Why?
|
| Fluorescent Antibody Technique | 2 | 2011 | 189 | 0.150 |
Why?
|
| Xenograft Model Antitumor Assays | 3 | 2014 | 259 | 0.150 |
Why?
|
| Sensitivity and Specificity | 2 | 2015 | 562 | 0.140 |
Why?
|
| Pseudopodia | 2 | 2007 | 15 | 0.140 |
Why?
|
| Dietary Supplements | 2 | 2021 | 208 | 0.140 |
Why?
|
| AMP-Activated Protein Kinases | 1 | 2016 | 58 | 0.130 |
Why?
|
| Epidermal Growth Factor | 2 | 2007 | 68 | 0.130 |
Why?
|
| PTEN Phosphohydrolase | 1 | 2016 | 54 | 0.130 |
Why?
|
| bcl-Associated Death Protein | 1 | 2014 | 9 | 0.130 |
Why?
|
| Protein Binding | 1 | 2018 | 972 | 0.130 |
Why?
|
| Pregnenolone | 1 | 2014 | 10 | 0.120 |
Why?
|
| Linear Models | 1 | 2015 | 275 | 0.120 |
Why?
|
| Proto-Oncogene Proteins c-kit | 1 | 2013 | 14 | 0.120 |
Why?
|
| Hela Cells | 1 | 2015 | 366 | 0.120 |
Why?
|
| Organometallic Compounds | 1 | 2014 | 73 | 0.110 |
Why?
|
| Leukemia, Myeloid, Acute | 1 | 2013 | 30 | 0.110 |
Why?
|
| Mice, Hairless | 1 | 2013 | 7 | 0.110 |
Why?
|
| Eukaryotic Initiation Factor-4E | 1 | 2012 | 15 | 0.110 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 2 | 2014 | 623 | 0.110 |
Why?
|
| RNA, Neoplasm | 1 | 2012 | 26 | 0.110 |
Why?
|
| Transplantation, Heterologous | 1 | 2012 | 90 | 0.110 |
Why?
|
| rho GTP-Binding Proteins | 1 | 2012 | 22 | 0.100 |
Why?
|
| Adenylate Kinase | 1 | 2012 | 14 | 0.100 |
Why?
|
| Catenins | 1 | 2011 | 3 | 0.100 |
Why?
|
| bcl-X Protein | 1 | 2011 | 27 | 0.100 |
Why?
|
| Antibiotics, Antineoplastic | 1 | 2012 | 44 | 0.100 |
Why?
|
| RNA, Messenger | 2 | 2014 | 1207 | 0.100 |
Why?
|
| Enzyme Activation | 3 | 2013 | 444 | 0.100 |
Why?
|
| Sirolimus | 1 | 2012 | 60 | 0.100 |
Why?
|
| bcl-2-Associated X Protein | 1 | 2011 | 77 | 0.100 |
Why?
|
| Reproducibility of Results | 1 | 2015 | 935 | 0.100 |
Why?
|
| Caspase 3 | 1 | 2012 | 207 | 0.100 |
Why?
|
| Cadherins | 1 | 2011 | 90 | 0.100 |
Why?
|
| Binding Sites | 1 | 2012 | 651 | 0.090 |
Why?
|
| Postmenopause | 2 | 2021 | 128 | 0.090 |
Why?
|
| Obesity | 1 | 2017 | 1067 | 0.080 |
Why?
|
| Asteraceae | 1 | 2007 | 3 | 0.080 |
Why?
|
| Saponins | 1 | 2007 | 6 | 0.080 |
Why?
|
| Focal Adhesion Protein-Tyrosine Kinases | 2 | 2005 | 19 | 0.080 |
Why?
|
| Focal Adhesion Kinase 1 | 2 | 2005 | 19 | 0.080 |
Why?
|
| Triterpenes | 1 | 2007 | 14 | 0.080 |
Why?
|
| Genes, Dominant | 1 | 2007 | 18 | 0.070 |
Why?
|
| Optical Fibers | 1 | 2006 | 5 | 0.070 |
Why?
|
| Molecular Diagnostic Techniques | 1 | 2007 | 14 | 0.070 |
Why?
|
| Fiber Optic Technology | 1 | 2006 | 9 | 0.070 |
Why?
|
| Optics and Photonics | 1 | 2007 | 28 | 0.070 |
Why?
|
| Protein-Tyrosine Kinases | 2 | 2005 | 132 | 0.070 |
Why?
|
| Diagnostic Imaging | 1 | 2007 | 53 | 0.070 |
Why?
|
| Gene Expression Regulation | 1 | 2012 | 1015 | 0.070 |
Why?
|
| NF-kappa B | 1 | 2009 | 339 | 0.070 |
Why?
|
| Transfection | 1 | 2007 | 523 | 0.070 |
Why?
|
| Microscopy, Confocal | 2 | 2004 | 218 | 0.060 |
Why?
|
| Angiogenesis Inhibitors | 1 | 2005 | 59 | 0.060 |
Why?
|
| Inflammation | 2 | 2019 | 618 | 0.060 |
Why?
|
| Phenotype | 1 | 2005 | 689 | 0.050 |
Why?
|
| Cell Membrane | 1 | 2005 | 381 | 0.050 |
Why?
|
| Flavonoids | 1 | 2002 | 87 | 0.050 |
Why?
|
| Mammary Neoplasms, Animal | 1 | 2002 | 30 | 0.050 |
Why?
|
| Gene Expression Profiling | 1 | 2005 | 626 | 0.050 |
Why?
|
| Imaging, Three-Dimensional | 1 | 2002 | 84 | 0.050 |
Why?
|
| Culture Media, Conditioned | 1 | 2019 | 46 | 0.040 |
Why?
|
| 3T3-L1 Cells | 1 | 2019 | 16 | 0.040 |
Why?
|
| Culture Media | 1 | 2019 | 90 | 0.040 |
Why?
|
| Flow Cytometry | 2 | 2014 | 399 | 0.040 |
Why?
|
| Structure-Activity Relationship | 1 | 2019 | 409 | 0.040 |
Why?
|
| Fatty Acids, Omega-6 | 1 | 2017 | 11 | 0.040 |
Why?
|
| Phosphorylation | 2 | 2014 | 928 | 0.040 |
Why?
|
| STAT Transcription Factors | 1 | 2014 | 12 | 0.030 |
Why?
|
| Reference Standards | 1 | 2014 | 52 | 0.030 |
Why?
|
| Calibration | 1 | 2014 | 56 | 0.030 |
Why?
|
| Immunoenzyme Techniques | 1 | 2014 | 108 | 0.030 |
Why?
|
| beta Catenin | 1 | 2014 | 48 | 0.030 |
Why?
|
| Tumor Burden | 1 | 2014 | 77 | 0.030 |
Why?
|
| Mastocytosis | 1 | 2013 | 2 | 0.030 |
Why?
|
| Proto-Oncogene Proteins c-vav | 1 | 2013 | 6 | 0.030 |
Why?
|
| Mice, Inbred C3H | 1 | 2013 | 84 | 0.030 |
Why?
|
| Drug Synergism | 1 | 2014 | 177 | 0.030 |
Why?
|
| Cross-Sectional Studies | 1 | 2021 | 2721 | 0.030 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 1 | 2014 | 448 | 0.030 |
Why?
|
| Mutation, Missense | 1 | 2013 | 83 | 0.030 |
Why?
|
| Kidney | 1 | 2014 | 337 | 0.020 |
Why?
|
| Liver | 1 | 2014 | 479 | 0.020 |
Why?
|
| Mice, Inbred C57BL | 1 | 2013 | 1609 | 0.020 |
Why?
|
| Middle Aged | 1 | 2021 | 10129 | 0.020 |
Why?
|
| Spectrometry, Mass, Electrospray Ionization | 1 | 2007 | 132 | 0.020 |
Why?
|
| Magnetic Resonance Spectroscopy | 1 | 2007 | 289 | 0.020 |
Why?
|
| Contrast Media | 1 | 2007 | 92 | 0.020 |
Why?
|
| Adult | 1 | 2021 | 11712 | 0.020 |
Why?
|
| Streptavidin | 1 | 2004 | 6 | 0.020 |
Why?
|
| Fluorometry | 1 | 2004 | 17 | 0.010 |
Why?
|
| Mouth Mucosa | 1 | 2004 | 34 | 0.010 |
Why?
|
| Staining and Labeling | 1 | 2004 | 105 | 0.010 |
Why?
|
| Biopsy | 1 | 2004 | 164 | 0.010 |
Why?
|
| Mouth Neoplasms | 1 | 2004 | 71 | 0.010 |
Why?
|
| Precancerous Conditions | 1 | 2004 | 82 | 0.010 |
Why?
|
| Estrogens, Non-Steroidal | 1 | 2002 | 19 | 0.010 |
Why?
|
| Plant Preparations | 1 | 2002 | 27 | 0.010 |
Why?
|
| Proto-Oncogene Proteins | 1 | 2002 | 239 | 0.010 |
Why?
|
| Mice, Inbred BALB C | 1 | 2002 | 661 | 0.010 |
Why?
|